D&A at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Axsome Therapeutics's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Axsome Therapeutics's D&A?
- Axsome Therapeutics (AXSM) reported D&A of $116K in Q1 2026.
- How has Axsome Therapeutics's D&A changed year-over-year?
- Axsome Therapeutics's D&A decreased by 22.1% year-over-year, from $149K to $116K.
- What is the long-term trend for Axsome Therapeutics's D&A?
- Over 4 years (2021 to 2025), Axsome Therapeutics's D&A has grown at a 60.4% compound annual growth rate (CAGR), from $76K to $503K.
- What does D&A mean?
- The total non-cash expense for the aging of physical and intangible assets.
- How do you interpret D&A?
- A steady increase may indicate a growing asset base, while a decrease may suggest aging infrastructure or reduced capital investment.
- How does D&A compare across companies?
- Standard metric for assessing capital intensity across all industries.